ReviewBiomedicines2022
Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- A case of dupilumab-induced psoriatic alopecia.Skin health and disease · 2026Article
- Celastrol attenuates Th1- and Th2-driven skin inflammation in 2D and 3D in vitro models.Scientific reports · 2026Article
- Understanding Biologics in CRSwNP: Related Events and Insights.Current allergy and asthma reports · 2026Review
- Paradoxical Cutaneous Reaction: Secukinumab-Associated PLEVA in Palmoplantar Pustulosis.Journal of inflammation research · 2026Article
- Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China.Frontiers in immunology · 2026Article
- Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort.Frontiers in immunology · 2025Observational
- Paradoxical lichenoid drug eruption following dupilumab use for atopic dermatitis: A case report.SAGE open medical case reports · 2025Article
- Adalimumab-Induced Cutaneous Lupus Erythematosus: Cases Presenting With Malar Rash and Panniculitis.Clinical case reports · 2025Article
- Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'".American journal of clinical dermatology · 2024Article
- Secukinumab-Aggravated Disseminated Discoid Lupus Erythematosus Misdiagnosed as Psoriasis.Cureus · 2024Article
- Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab.Cureus · 2024Article
- Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors.International journal of molecular sciences · 2024Review
- Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis.Frontiers in immunology · 2024Article
- Immune Portrayal of a New Therapy Targeting Microbiota in an Animal Model of Psoriasis.Journal of personalized medicine · 2023Article
- Review
- Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.Journal of clinical medicine · 2023Article
- Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis.Clinical, cosmetic and investigational dermatology · 2023Article
- A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis.Clinical, cosmetic and investigational dermatology · 2023Article
- The Intriguing Links between Psoriasis and Bullous Pemphigoid.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted biologic agents have dramatically changed the therapeutic landscape for immune-mediated inflammatory diseases, particularly in rheumatology and dermatology. Their introduction has resulted in a paradigm shift, i.e., they produce significant clinical improvements in most patients with such diseases. Nevertheless, a variety of adverse reactions associated with these agents have been observed, including so-called paradoxical reactions (PRs), which are a new class of adverse events. PRs involve the de novo development or worsening of immune-mediated inflammatory disease during treatment with a targeted biologic agent that is commonly used to treat the idiopathic counterpart of the drug-induced reaction. In addition, the efficacy of biologic agents targeting individual cytokines and the existence of PRs to them have provided proof that cytokines are key drivers of various immune-mediated inflammatory diseases and helped researchers elucidate the molecular pathways underlying the pathophysiology of these diseases. Here, a comprehensive review of the targeted biologic agents used to treat immune-mediated inflammatory diseases, particularly psoriasis and atopic dermatitis, is provided, with a specific focus on biologic agents that inhibit cytokine signaling involving tumor necrosis factor-α, interleukin (IL)-12/23 (p40), IL-17A (and the IL-17 receptor [R]), IL-23 (p19), and the IL-4Rα, and their associated PRs. The characteristic clinical manifestations and potential immunological mechanisms of the PRs induced by these biologic agents are also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.